Why the study?
Prognosis remains poor for relapsed or refractory Ewing sarcoma with limited post-first-line options, and data on oral etoposide are limited in adults despite efficacy in paediatric settings.
Does oral etoposide improve outcomes in adolescent and adult patients with relapsed or refractory Ewing sarcoma?
Does oral etoposide improve outcomes in adolescent and adult patients with relapsed or refractory Ewing sarcoma?
Oral etoposide demonstrates antitumour activity and durable responses in adult patients with relapsed or refractory Ewing sarcoma, despite prior exposure to intravenous etoposide.
May support palliative use in select adults; leaves open prospective confirmation before broader adoption.
Prognosis remains poor for patients with relapsed or refractory Ewing sarcoma, with limited treatment options after first-line therapy. Oral etoposide has efficacy in the paediatric setting; however, data are limited in adults. A retrospective analysis was conducted on 33 patients with relapsed or refractory Ewing sarcoma who completed at least one cycle of oral etoposide at the Peter MacCallum Cancer Centre from 2005 to 2020. The median age at diagnosis and first relapse was 21 and 23 years, respectively. All patients had prior exposure to intravenous etoposide. Nine patients (27%) had stable disease for at least 6 months, and six patients (18%) had a partial response. The clinical benefit rate was 45%. The median PFS was 3.6 months (95% CI: 1.7-5.5), and OS was 8.5 months (95% CI: 4.1-13.0). Despite prior exposure, oral etoposide demonstrated antitumour activity and durable responses in the relapsed or refractory setting for adult patients with Ewing sarcoma.
No takes yet. Share an insight, caveat, or question.
Kostos et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: